Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Tolerability of Plitidepsin in Advanced Dedifferentiated Liposarcoma (Phase II)
2009-010980-18Phase 2Active
- Sponsor
- PharmaMar
- Start
- May 2009
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Cyclic Peptides → Modified Peptides → Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of plitidepsin in dedifferentiated liposarcoma (DDL) and Liposarcoma, sponsored by PharmaMar. Primary endpoint: Progression-free survival rate at 3 months (PFS3). Started May 2009; status: active.
02
Drugs
plitidepsin
03
Conditions
dedifferentiated liposarcoma (DDL)Liposarcoma
Beyond the preview
Go deeper on 2009-010980-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-010980-18.